Bioprocessing Summit: Time to rethink your HCP Coverage analysis?

13 August 2019

Your HCP analysis should be both reactive to broader populations of HCPs and more specific to HCPs likely to be in the final product.

However, with current methods, based on 2D PAGE and Western Blot, it is difficult to know if both of these conditions are met.

If you’re in Boston today, you can experience Ejvind Mortz present the NEW Alphalyse Coverage Analysis based on plate-based immunocapture combined with LC-MS, which provides all of the following:

✔️ List of HCPs recognized by ELISA antibodies
✔️ List of HCPs in mock or early process sample
✔️ HCP coverage
✔️ Specific HCP coverage of drug substance

Find out more on our website

or on the event site: